Literature DB >> 29299413

Raising the bar: the future of EGFR inhibition in non-small lung cancer.

Amanda J Redig1,2,3.   

Abstract

Entities:  

Year:  2017        PMID： 29299413      PMCID： PMC5750143          DOI： 10.21037/tlcr.2017.10.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

1.  EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Authors:  Dalia Ercan; Hwan Geun Choi; Cai-Hong Yun; Marzia Capelletti; Ting Xie; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2015-05-06       Impact factor: 12.531

Review 2.  Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?

Authors:  Chee-Seng Tan; Byoung Chul Cho; Ross A Soo
Journal:  Lung Cancer       Date:  2017-02-22       Impact factor: 5.705

3.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

Review 4.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Cancer Discov       Date:  2016-03-11       Impact factor: 39.397

5.  Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Authors:  Susanne Saussele; Marie-Paloma Krauss; Rüdiger Hehlmann; Michael Lauseker; Ulrike Proetel; Lida Kalmanti; Benjamin Hanfstein; Alice Fabarius; Doris Kraemer; Wolfgang E Berdel; Martin Bentz; Peter Staib; Maike de Wit; Martin Wernli; Florian Zettl; Holger F Hebart; Markus Hahn; Jochen Heymanns; Ingo Schmidt-Wolf; Norbert Schmitz; Michael J Eckart; Winfried Gassmann; Andrea Bartholomäus; Antonio Pezzutto; Elisabeth Oppliger Leibundgut; Dominik Heim; Stefan W Krause; Andreas Burchert; Wolf-Karsten Hofmann; Joerg Hasford; Andreas Hochhaus; Markus Pfirrmann; Martin C Müller
Journal:  Blood       Date:  2015-04-27       Impact factor: 22.113

6.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Authors:  Suresh S Ramalingam; James C-H Yang; Chee Khoon Lee; Takayasu Kurata; Dong-Wan Kim; Thomas John; Naoyuki Nogami; Yuichiro Ohe; Helen Mann; Yuri Rukazenkov; Serban Ghiorghiu; Daniel Stetson; Aleksandra Markovets; J Carl Barrett; Kenneth S Thress; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-08-25       Impact factor: 44.544

7.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

8.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

9.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Authors:  Glenwood Goss; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Jong Seok Lee; Gee-Chen Chang; Lucio Crino; Miyako Satouchi; Quincy Chu; Toyoaki Hida; Ji-Youn Han; Oscar Juan; Frank Dunphy; Makoto Nishio; Jin-Hyoung Kang; Margarita Majem; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Tetsuya Mitsudomi
Journal:  Lancet Oncol       Date:  2016-10-14       Impact factor: 41.316

10.  Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Authors:  Yong Jia; Cai-Hong Yun; Eunyoung Park; Dalia Ercan; Mari Manuia; Jose Juarez; Chunxiao Xu; Kevin Rhee; Ting Chen; Haikuo Zhang; Sangeetha Palakurthi; Jaebong Jang; Gerald Lelais; Michael DiDonato; Badry Bursulaya; Pierre-Yves Michellys; Robert Epple; Thomas H Marsilje; Matthew McNeill; Wenshuo Lu; Jennifer Harris; Steven Bender; Kwok-Kin Wong; Pasi A Jänne; Michael J Eck
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.